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Illness represents a dysregulation of body homeostasis with consequences to physical and mental well-
being, negative impact on functionality and life expectancy, prompting the concept of treat to target for 
many conditions. This strategy has however not yet been operationalized for the care of persons with 
fibromyalgia (FM). FM, defined by the American College of Rheumatology (ACR) preliminary 2010 
diagnostic criteria and modified 2011 criteria, is characterized by widespread body pain and associated 
core symptoms of  sleep disturbance, fatigue and cognitive problems as well as other somatic and mood 
complaints, has  immediate effect on health-related quality of life (HRQoL), but with lesser known long 
standing effects (1-3). Although not yet fully understood, the pathogenesis of FM is likely centered in the 
nervous system rather than the musculoskeletal system as the taxonomy “fibromyalgia” implies (4). FM 
may occur as a unique diagnosis, but the association with other somatic and mental disorders broadens the 
impact of this condition (3).  
 
The treat to target principle should be considered for FM care even though numerous uncertainties exist. 
In order to adhere to these principles the following need clarification: choice of ideal health care setting; a 
standard for clinical diagnosis; and a universal treatment algorithm. A move towards treat to target in FM 
is important for several reasons. Firstly, FM is common, with disease prevalence worldwide of at least 
2%, and with prolonged persistence of symptoms (5). Secondly, FM impacts HRQoL, personal and social 
functioning, and incurs both direct and indirect health costs (4). Thirdly, the co-association with other 
inflammatory rheumatic diseases will impact treatment decisions and outcome for these illnesses (6). 
Therefore a more structured approach to management of FM should replace the current treatment 
paradigm that is often haphazard and is largely based on individual physician preferences (7). 
 
 
What is needed?  
The premise for “treat to target” is to apply a treatment strategy that improves patient outcome assessed 
with a pre-specified measure that captures illness severity. Beyond current symptom control, the 
overriding objective is to improve long-term functional outcomes with prevention of adverse 
consequences to health by applying  an effective treatment algorithm, supported by evidence from 
randomised clinical trials, with objective of disease remission or very low disease activity (8).  
 
Treat to target should adhere to a number of elementary steps including: clear disease definition, 
knowledge of long-term consequences of inadequate treatment, substantial effect for treatments and 
known duration of treatment, defined meaningful outcome measurements and accepted response criteria. 
Furthermore, an understanding of the underlying pathophysiologic processes will help identify prognostic 
and prevention factors.  In this context we will address concepts of treat to target pertaining to FM by 
examining the current evidence with the aim of initiating dialogue. 
 
 
 
How does fibromyalgia measure up to the critical elements that comprise a treat-to-target strategy?  
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1. Is fibromyalgia a clearly defined condition?   
FM is a recognized medical condition, with ACR defined preliminary criteria and severity scales (2).  The 
precise diagnosis in an individual patient may however be elusive, with symptoms present for years 
leading to many health care encounters and diagnostic delay possibly adversely affecting outcome (9). 
Those familiar with treating FM contend that “they can recognise FM”, but experts still debate practical 
clinical diagnostic criteria (7, 10). Issues include the precise definition of widespread pain, and the 
relevance of co-associated symptoms, that vary both within a patient over time as well as between 
patients (11).  
 
Widespread pain is universally recognized as the cardinal symptom of FM, with variability in the 
presence of other core symptoms as identified by the OMERACT working group (11). Core symptoms 
may be expressed differently between patients, contributing different weights to global health status. 
Therefore weighting symptoms for an individual, in line with the general concepts of using patient 
reported outcomes (PROs), may more accurately reflect global health status than using a generic 
measurement  The importance of such PROs probing of many relevant domains has influenced 
assessment in clinical trials, observational studies and clinical practice (12). Therefore identifying the 
symptom of greatest importance can anchor treatment in a patient-tailored approach, prompting attempts 
to subgroup patients to help direct treatments (13).  
 
2. Can fibromyalgia be prevented?  
Prediction, prevention and early detection of disease represent an ideal. Factors predicting onset of FM 
are largely unknown, although genetic predisposition, adverse psychosocial lifetime experience, poor 
stress response system and triggering events may play a role (3, 4). Some regional pains may even evolve 
into more wi espread pain. It is largely unknown whether early FM detection will influence outcome, but 
intuitively prompt recognition of FM or of a symptom pattern that suggests a diathesis towards 
developing FM might lead to earlier intervention with non-pharmacological approaches.   Earlier 
detection of FM may be facilitated by education of and a heightened awareness by primary health care 
providers, and/or by using screening measures for the core symptoms of (or risk factors for) fibromyalgia 
in routine practice.  Various screening questionnaires have been proposed to help identify FM or 
discriminate FM from other rheumatic conditions, but have not to date demonstrated an effect on 
outcome. (10, 14-16). At this time, the ACR criteria and current evidence-based guidelines strongly 
recommend against assigning a diagnosis of FM based only on completion of a questionnaire as the 
clinical encounter and narrative report of the patient must still remain the gold standard for diagnosis (1, 
17). 
 
3. Are the long term consequences of fibromyalgia known? 
Long-term observational studies give insight into disease natural history, with poor control adversely 
affecting outcome. Although FM is associated with poor HRQoL and considerable functional impairment 
in the present, long term effects are largely unknown, but with indications that symptoms persist over 
time (3, 4). Adolescents with juvenile-onset FM had a high likelihood of continued symptoms into 
adulthood, with consequent physical and emotional impairment, and poorer educational achievement (18).  
It is reasonable to believe that outcome may be affected by variables such as delayed diagnosis, symptom 
duration, other comorbidities, and environmental and social factors. It is also possible that cognitive styles 
such as catastrophizing, known to be associated with poorer outcomes in all chronic pain conditions, 
could be prevented or reduced by earlier (especially non-pharmacological) interventions that enable active 
participation by the patient in preventing symptoms and associated dysfunction rather than being the 
passive victim (19).  It is also not known whether patients maintain their characteristic phenotype and 
disease expression with time, or whether disease expression changes. For example, it is possible that an 
individual core symptom may emerge or decline as a predominant symptom.  
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Reports on all-cause mortality for FM are conflicting, with reports of no difference or increased mortality 
rates compared to population norms. Wolfe and colleagues reported similar standardised mortality ratios 
for FM compared to the US population, but with FM associated with an increased standardized mortality 
odds ratio (OR) for suicide (OR 3.31, 95% CI 2.15-5.11), and for accidental deaths (OR 1.45, 95% CI 
1.02-2.06), but not for malignancy (20).  Similarly, overall mortality was not increased for a Danish FM 
cohort followed for a total of 5,295 person-years, but with increased risk of death from suicide, liver 
disease and cardiovascular disease (21).   Suicidal ideation is reported to occur in almost half of FM 
patients, and risk of suicide was greater for FM patients than those with low back pain (22).  
 
Another factor that influences life expectancy is injury. The incidence rate ratio for motor vehicle 
accidents for adults with FM living in Ontario, Canada, where the driver required a visit to an emergency 
room, was 2.44 compared with the population norm (95% CI 2.27-2.63, p< 0.001) (23). Therefore there is 
a picture emerging of a possible increased rate of accidental death (possibly related to cognitive 
difficulties innate to FM or medications) as well as suicidal deaths related to associated depression (22). 
An intriguing concept is that biological age may be affected by FM.  Leucocyte telomere length was 
shorter in FM patients than controls, but with a significant effect observed for those FM patients with 
both high pain and high depression levels (24).   
 
Finally, the long-term socioeconomic consequences for the individual and society must be acknowledged. 
Costs to society include the direct and indirect health related costs, employment status, productivity and 
disablement (25).   
 
4. Are there effective treatments for fibromyalgia? 
At this time, a treatment plan for FM must begin with non-pharmacologic strategies including education, 
establishing individualized and realistic goals of therapy, patient engagement, and implementation of self-
management techniques. Selective drug treatments may also we used with diligent monitoring of efficacy 
and side effect profile. Contrary to conditions where treatments are known to substantially alter or control 
disease, management strategies for FM fall short of the mark, without a recommended ideal health care 
setting, or universally accepted treatment algorithm or “gold standard”, or suggested duration of 
treatments. Therefore the concept of intensive treatments or “tight control” is at this time outside the 
scope of this dialogue. Although many interventions show statistical significance, clinically meaningful 
and continued effect remains questionable. A stepwise treatment approach has recently been 
recommended by German, Canadian and Israeli interdisciplinary guidelines, beginning with non-
pharmacologic strategies of active patient participation championing self-management strategies, and 
with discretionary medication use to ensure that side effects do not eclipse the positive effects (26). 
 
Current drug treatments for FM are imperfect, offering mostly modest benefit for the majority of patients, 
with only a few experiencing substantial effect. For example, a Cochrane review of the effect of serotonin 
norepinephrine reuptake inhibitors (SNRI’s) for FM reported that the average effect of drug treatments 
(compared to controls) was small (27). The risk ratio (RR) was about 1.5 for 50% or more pain relief 
compared to placebo for most,  and the number needed to treat to benefit (NNTB) and number needed to 
harm (NNTH) was in the order of 10 for each (27). Only very few patients in trial settings reach a pain 
level of <4 (low pain) on a visual analogue scale. Non pharmacological treatments including 
multidisciplinary approaches and those that have a mind-body component hold promise, but may not be 
universally available (28, 29). Acceptance-based CBT  had a NNTB of 2 for 20% improvement for 
HRQoL compared to best available drug treatment (duloxetine, pregabalin)(29).  A recent network meta-
analysis of all treatments for FM reported that the average benefits of pharmacologic treatments was of 
questionable clinical relevance and that the evidence for non-pharmacological interventions is limited 
(30). Moreover, although there is a growing body of published scientific evidence for complementary and 
alternative therapies for FM, methodological flaws identified in systematic reviews preclude conclusions 
about efficacy and safety for many (30, 31).   
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How then can this inform FM care? As a first step, a treatment algorithm, with a sound evidence base, 
must be developed and agreed upon by the international health community. Current algorithms, such as 
that developed in Germany, could be examined for universal applicability (32). Taking into account the 
current evidence and combined with clinical judgement, strategies that promote physical activity and 
stress reduction, and require active patient engagement have value and should be encouraged. With only 
three drugs, pregabalin, duloxetine and milnacipran, approved for treatment of FM in the United States 
and with more limited approval worldwide, pharmacologic treatment options are limited. Selected 
pharmacotherapy may be chosen according to the most prominent symptom with tricyclic drugs, 
serotonin-norepinephrine reuptake inhibitors, and gabapentinoids identified as classes of drugs with the 
greatest benefits.  Fatigue is a challenging symptom, with no consistent evidence for pharmacologic 
treatment, but evidence for physical activity and cognitive behavioral therapies as the best current strategy 
(33, 34) .  With the exception of a single study each of tramadol and tramadol/paracetamol, there are no 
randomized controlled trials of opioids in FM, and there is virtually unanimity that this class of drugs 
should be avoided (26).  In this setting of symptom heterogeneity, FM represents the prototype condition 
that calls for patient tailored individualized treatments. A starting treatment algorithm is suggested 
(Figure 1. Algorithm for Fibromyalgia care). 
 
 
 
5. Is there a target for disease outcome for fibromyalgia?  
A target should be a standard outcome measurement that is reliable, easy to perform, clinically 
meaningful, captures disease severity and has a defined minimal threshold for improvement. 
Consideration could even be given to a simple concept of disease status as active, or partial or complete 
remission,  but simply focussing on a single symptom such as pain intensity is no longer a tenable 
outcome measure (32, 35). Unique target challenges posed by FM include the heterogeneity of symptoms 
and possible differing outcome goals for patient or physician. Subgrouping patients may help focus 
towards a specific symptom or target, such as categorizing patients according to psychological factors, i.e. 
low or high psychological problems, with those with mostly physical symptoms likely easier to manage 
compared to those with a high burden of psychological distress (13). The latter could theoretically benefit 
from more focussed psychologically directed treatments  
 
Simplistically, remission may be defined by the patient stating that “I am no longer a patient and no 
longer suffer due to my pain (which may still be present) (30)”.  As patient narrative may be difficult to 
anchor multiple complaints, the patient global assessment (PGA), encompassing all domains may have 
use. Although confounded by short term fluctuating symptoms, and longer term recall bias, the PGA is a 
simple and reliable clinical assessment, whereas a physician global assessment may be less reliable for 
subjective complaints (36).   
 
Another target could be to achieve a threshold value on a composite measure. Questionnaires reflecting 
outcomes include the Fibromyalgia Impact Questionnaire (FIQ) or the updated revised FIQ (FIQR), the 
2011 Fibromyalgia Survey Criteria and the Patient Health Questionnaire 15 (PHQ15) (2, 37-39). These 
composite measures mostly address various dimensions of disease, with some assessing function, but with 
risk that the final score may not sufficiently reflect the effect of a specific domain within a group. The 
FIQ, or FIQR are the most widely used measures, but score calculation is complex and less applicable to 
clinical care. A target may however be defined by a FIQ total score <39.  However, in a clinical study of 
group acceptance and commitment therapy which used the FIQ, no patient reached a FIQ score <39 (29). 
Some participants in multicomponent trials reported to be “no patients any more” (28). A recent 
modification of the FIQR, the Symptom Impact Questionnaire (SIQR), similarly complex to calculate, 
has been proposed as a disease-neutral measurement (16). The FM Survey Criteria in contrast, focuses 
specifically on symptoms without reference to functional status, quality of life or life participation, and 
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with a target defined as a total score of <12. The PHQ15 as a generic measure of somatic symptom 
burden is easy to complete and calculate, and a threshold of <5 could may represent a remission (39).  
 
An individualized personal target that may be applied in real world clinical practice may be an identified 
improvement in daily function, rather than specifically focussing on individual symptoms. Some 
standardized measurements do exist, but have not yet been applied to FM. Similarly, focussing towards 
short term goals that are readily tangible may be more meaningful to the patient than a calculated number 
on a questionnaire. Defining individual and realistic outcome goals, such as a 30% symptom relief and a 
specified goal for daily functional improvement, in a setting of shared-decision making, is an achievable 
and reasonable target that can be easily clinically applied (39). 
 
 
Can a treat to target strategy for fibromyalgia be suggested? 
The gaps in FM that must be closed to truly move towards a treat-to-target approach include the 
following: validation of existing diagnostic and treatment algorithms in different settings (primary care, 
rheumatology, pain medicine, and less developed countries); validation of individual tailored treatments 
versus a standard approach based on defined patient subgroups, and consensus on responder criteria to be 
used to assess treatment effects, especially for non-drug treatments. Poorly treated FM has immediate 
impact on physical and psychological well-being, with long-term consequences an emerging reality. 
Future study should be focussed to identifying persons at risk for FM to consider prevention strategies, 
examination of patient-tailored specific therapies, with the treatment goal of symptom relief and 
maintained function. These considerations should prompt management of FM beyond the immediate 
towards a wider vision of future health status, and that these principles should guide the research agenda.    
 
 
.    
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Initial assessment of patient with chronic widespread pain 
 
Complete medical, psychosocial and family history 
Physical examination 
 
Laboratory tests (CBC, TSH, CK, CRP, Vitamin D) 
any other test directed by findings on history and physical examination 
 
Confirm diagnosis Fibromyalgia 
 
Education and recommendation for regular health related physical activity for all 
Mind/body activity program 
 
 
Patient tailored treatment focussing on specific symptoms 
 Pain Sleep disturbance Mood disturbance Fatigue Impaired function 
Simple analgesic, 
acetaminophen 
Sleep hygiene Aerobic exercise  Address sleep 
problems 
Multimodal therapy 
Tricyclic agent, 
amitriptyline 
Tricyclic agent,  
amitriptyline 
Mental health 
specialist 
Physical activity Rehabilitation program 
Gabapentinoid, 
pregabalin 
Gabapentinoid,  
pregabalin 
Psychological 
therapies, e.g. CBT 
Psychological 
therapies, e.g. CBT 
 
SNRI,  
duloxetine, 
milnacipran 
Cyclobenzaprine SNRI 
duloxetine, 
milnacipran 
SNRI,  
duloxetine, 
milnacipran 
 
  SSRI,  
fluoxetine, 
paroxetine 
  
 
CBC=complete blood count, TSH= thyroid stimulating hormone, CK=creatine kinase, CRP=C-reactive 
protein, SNRI=serotonin norepinephrine reuptake inhibitor, CBT=cognitive behavioural therapy, 
SSRI=selective serotonin reuptake inhibitor. 
 
Figure 1.  Algorithm for Fibromyalgia care 
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